DelveInsight’s “Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Obstructive Pulmonary Disease, historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Obstructive Pulmonary Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Obstructive Pulmonary Disease Market Forecast
Some of the key facts of the Chronic Obstructive Pulmonary Disease Market Report:
- The Chronic Obstructive Pulmonary Disease market size was valued approximately USD 12 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In 2022, the number of identified cases of Chronic Obstructive Pulmonary Disease (COPD) in the 7MM was recorded at 32,796,595. It is projected that this diagnosed population of COPD within the 7MM will see a rise over the study period spanning from 2019 to 2032.
- The projections indicate a greater diagnosed prevalence of COPD in the United States, reaching 18,147,244 diagnosed cases in 2022 compared to the other 7MM countries. This number is anticipated to escalate during the forecast period from 2023 to 2032
- In 2022, among the five European countries assessed, Germany reported the highest diagnosed prevalent population of COPD, totaling 3,775,071 cases. Following Germany, Italy and France recorded lower figures. Conversely, Spain had the lowest diagnosed prevalent population of COPD in the same year, with 1,437,542 cases.
- Key Chronic Obstructive Pulmonary Disease Companies: Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others
- Key Chronic Obstructive Pulmonary Disease Therapies: Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others.
- The Chronic Obstructive Pulmonary Disease epidemiology based on gender analyzed that the majority of cases of COPD are of female as compared to male, in the US
- The Chronic Obstructive Pulmonary Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Obstructive Pulmonary Disease pipeline products will significantly revolutionize the Chronic Obstructive Pulmonary Disease market dynamics.
Chronic Obstructive Pulmonary Disease Overview
Chronic obstructive pulmonary disease (COPD) is a widespread, treatable, and avoidable illness marked by ongoing respiratory symptoms and restricted airflow because of abnormalities in the airways or alveoli, which are typically brought on by prolonged exposure to harmful particles or gases.
Get a Free sample for the Chronic Obstructive Pulmonary Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
Chronic Obstructive Pulmonary Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chronic Obstructive Pulmonary Disease Epidemiology Segmentation:
The Chronic Obstructive Pulmonary Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Chronic Obstructive Pulmonary Disease
- Prevalent Cases of Chronic Obstructive Pulmonary Disease by severity
- Gender-specific Prevalence of Chronic Obstructive Pulmonary Disease
- Diagnosed Cases of Episodic and Chronic Chronic Obstructive Pulmonary Disease
Download the report to understand which factors are driving Chronic Obstructive Pulmonary Disease epidemiology trends @ Chronic Obstructive Pulmonary Disease Epidemiology Forecast
Chronic Obstructive Pulmonary Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Obstructive Pulmonary Disease market or expected to get launched during the study period. The analysis covers Chronic Obstructive Pulmonary Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Obstructive Pulmonary Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Chronic Obstructive Pulmonary Disease Therapies and Key Companies
- Itepekimab/SAR440340/REGN3500: Regeneron Pharmaceuticals/Sanofi
- Dupilumab/SAR231893 (Dupixent): Regeneron Pharmaceuticals/Sanofi
- Tozorakimab (MEDI3506): AstraZeneca/MedImmune LLC
- FASENRA (Benralizumab): AstraZeneca
- Tezspire (Tezepelumab): AstraZeneca
- Astegolimab (MSTT1041A, AMG 282, RG6149): Genentech, Inc.
- SB240563 (Mepolizumab)/NUCALA: GlaxoSmithKline
- Ensifentrine (RPL554): Verona Pharma plc
- EP395: EpiEndo Pharmaceuticals
- SelK2: Tetherex Pharmaceuticals
- Mitiperstat (AZD4831): AstraZeneca
- CHF6001/Tanimilast: Chiesi Farmaceutici S.p.A.
- SNG001 (IFN-β): Synairgen Research Ltd.
- Acumapimod (BCT-197): Mereo Biopharma
- Zofin: Organicell Regenerative Medicine
- PUL-042: Pulmotect, Inc.
- MV130: Inmunotek S.L.
- GSK3923868: GlaxoSmithKline
- PUR1800: PULMATRiX
- GRC 39815: GLENMARK PHARMACEUTICALS LTD
- DMX-700: Dimerix Limited
Discover more about therapies set to grab major Chronic Obstructive Pulmonary Disease market share @ Chronic Obstructive Pulmonary Disease Treatment Landscape
Chronic Obstructive Pulmonary Disease Market Strengths
- The prevalence of COPD is increasing dramatically in recent years due to the higher smoking prevalence and aging populations in many countries.
Chronic Obstructive Pulmonary Disease Market Opportunities
- There is a growing demand for fixed-dose combinations as combination therapy can enhance and prolong the effects of monocomponent.
Scope of the Chronic Obstructive Pulmonary Disease Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Chronic Obstructive Pulmonary Disease Companies: Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others
- Key Chronic Obstructive Pulmonary Disease Therapies: Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others
- Chronic Obstructive Pulmonary Disease Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies
- Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Chronic Obstructive Pulmonary Disease Unmet Needs, KOL’s views, Analyst’s views, Chronic Obstructive Pulmonary Disease Market Access and Reimbursement
To know more about Chronic Obstructive Pulmonary Disease companies working in the treatment market, visit @ Chronic Obstructive Pulmonary Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Chronic Obstructive Pulmonary Disease Market Report Introduction
2. Executive Summary for Chronic Obstructive Pulmonary Disease
3. SWOT analysis of Chronic Obstructive Pulmonary Disease
4. Chronic Obstructive Pulmonary Disease Patient Share (%) Overview at a Glance
5. Chronic Obstructive Pulmonary Disease Market Overview at a Glance
6. Chronic Obstructive Pulmonary Disease Disease Background and Overview
7. Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Obstructive Pulmonary Disease
9. Chronic Obstructive Pulmonary Disease Current Treatment and Medical Practices
10. Chronic Obstructive Pulmonary Disease Unmet Needs
11. Chronic Obstructive Pulmonary Disease Emerging Therapies
12. Chronic Obstructive Pulmonary Disease Market Outlook
13. Country-Wise Chronic Obstructive Pulmonary Disease Market Analysis (2019–2032)
14. Chronic Obstructive Pulmonary Disease Market Access and Reimbursement of Therapies
15. Chronic Obstructive Pulmonary Disease Market Drivers
16. Chronic Obstructive Pulmonary Disease Market Barriers
17. Chronic Obstructive Pulmonary Disease Appendix
18. Chronic Obstructive Pulmonary Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/